About
Optune Lua® concurrent with PD-1/PD-L1 inhibitor or docetaxel is FDA-approved for adult patients with metastatic non–small cell lung cancer (mNSCLC) who have progressed on or after a platinum- based regimen.
Technologies
Cloudflare DNS
Mobile Friendly
Visual Website Optimizer
Vimeo
Google Tag Manager
Keywords
medical equipment manufacturing
oncology device
clinical trial data
electric field therapy
medical devices
ttfields
systemic immune response
docetaxel
mitotic disruption
medical equipment and supplies manufacturing
disrupt cancer cell division
b2b
quality of life
adverse events
pd-1/pd-l1 inhibitors
patient adherence
transducer arrays
overall survival benefit
immunogenic cell death
metastatic nsclc
combination therapy
tumor treating fields
device safety profile
electric fields
electrical therapy in oncology
wearable device
device portability
fda-approved cancer therapy
oncology
systemic toxicity
Company Information
-
Employees 0
